Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary

Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Levanon, 2008, New insights into the pathogenesis of serous ovarian cancer and its clinical impact, J Clin Oncol, 26, 5284, 10.1200/JCO.2008.18.1107 Malpica, 2004, Grading ovarian serous carcinoma using a two-tier system, Am J Surg Pathol, 28, 496, 10.1097/00000478-200404000-00009 Seidman, 2006, Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum, Gynecol Oncol, 103, 703, 10.1016/j.ygyno.2006.05.030 Gershenson, 2006, Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary, Obstet Gynecol, 108, 361, 10.1097/01.AOG.0000227787.24587.d1 NCCN Clinical Practice Guidelines in Oncology Schmeler, 2008, Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum, Gynecol Oncol, 108, 510, 10.1016/j.ygyno.2007.11.013 Shankar, 2006, Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials, J Nucl Med, 47, 1059 Costelloe, 2009, 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma, J Nucl Med, 50, 340, 10.2967/jnumed.108.058461 Williams, 2006 Hillner, 2008, Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry, J Nucl Med, 49, 1928, 10.2967/jnumed.108.056713 Hillner, 2008, Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry, J Clin Oncol, 26, 2155, 10.1200/JCO.2007.14.5631 Torizuka, 2002, Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose, Eur J Nucl Med Mol Imaging, 29, 797, 10.1007/s00259-001-0750-9 Prayer, 1993, CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer, J Comput Assist Tomogr, 17, 626, 10.1097/00004728-199307000-00021 Gu, 2009, CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis, Eur J Radiol, 71, 164, 10.1016/j.ejrad.2008.02.019 Havrilesky, 2005, FDG-PET for management of cervical and ovarian cancer, Gynecol Oncol, 97, 183, 10.1016/j.ygyno.2004.12.007 Erdi, 2000, Use of PET to monitor the response of lung cancer to radiation treatment, Eur J Nucl Med, 27, 861, 10.1007/s002590000258 Liao, 2012, Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer, Eur J Nucl Med Mol Imaging, 39, 27, 10.1007/s00259-011-1934-6 Chung, 2012, Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer, Ann Surg Oncol, 19, 1966, 10.1245/s10434-011-2153-x Tateishi, 2008, Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT, Radiology, 247, 189, 10.1148/radiol.2471070567 Gulec, 2011, The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy, Eur J Nucl Med Mol Imaging, 38, 1289, 10.1007/s00259-011-1758-4